The small-molecule inhibitor of survivin, YM 155, has shown promise for the treatment of solid tumours and lymphoma

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1659, 2008-01, pp. : 10-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma

By Lewis Karl   Samlowski Wolfram   Ward John   Catlett Joseph   Cranmer Lee   Kirkwood John   Lawson David   Whitman Eric   Gonzalez Rene  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 161-166

Springer Publishing Company

Access to resources Recommend Favorite

Merck KGaA's cilengitide, a vitronectin inhibitor designed to inhibit angiogenesis, has shown promise as a treatment for recurrent glioblastoma.

By  

Inpharma, Vol. 1, Iss. 1666, 2008-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

The Vx 001 [TERT572Y] vaccine has shown promise in the treatment of advanced non-small-cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1598, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Recent Advances on Small-Molecule Survivin Inhibitors

By  

Current Medicinal Chemistry, Vol. 22, Iss. 9, 2015-03 ,pp. : 1136-1146

Bentham Science Publishers

Access to resources Recommend Favorite

Topical becocalcidiol has shown promise in the treatment of patients with chronic plaque psoriasis

By  

Inpharma, Vol. 1, Iss. 1606, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite